Production (Stage)
Amylyx Pharmaceuticals, Inc.
AMLX
$5.31
-$0.05-0.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -218.86M | -301.74M | -259.47M | -165.87M | -71.10M |
| Total Depreciation and Amortization | 745.00K | 904.00K | 1.05M | 1.13M | 1.20M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 66.33M | 179.02M | 180.90M | 147.09M | 140.45M |
| Change in Net Operating Assets | -55.20M | -45.83M | -17.57M | -41.03M | -54.05M |
| Cash from Operations | -206.98M | -167.65M | -95.09M | -58.69M | 16.50M |
| Capital Expenditure | -36.30M | -36.36M | -36.70M | -869.00K | -1.06M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 67.48M | 112.01M | 68.30M | -114.44M | 37.94M |
| Cash from Investing | 31.18M | 75.65M | 31.60M | -115.31M | 36.88M |
| Total Debt Issued | 65.58M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.66M | 2.13M | 2.33M | 2.82M | 4.90M |
| Repurchase of Common Stock | -1.35M | -1.78M | -1.86M | -1.55M | -2.27M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 0.00 | 0.00 |
| Cash from Financing | 65.88M | 348.00K | 468.00K | 1.28M | 2.63M |
| Foreign Exchange rate Adjustments | -131.00K | -438.00K | 324.00K | -46.00K | -25.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -110.06M | -92.08M | -62.70M | -172.76M | 55.99M |